Saltar al contenido principal
Elsevier

Post-Authorization Safety Studies of Medicinal Products

The PASS Book

  • 1 Edición - 19 de junio de 2018
  • Última edición
  • Editores: Ayad K. Ali, Abraham G. Hartzema
  • Idioma: Inglés

Post-Authorization Safety Studies of Medicinal Products: The PASS Book bridges the gap in the literature by providing a complete look at post-authorization safety studies and impor… Leer más

Descripción

Post-Authorization Safety Studies of Medicinal Products: The PASS Book bridges the gap in the literature by providing a complete look at post-authorization safety studies and important pharmacoepidemiology and pharmacovigilance aspects. It covers various types and limitations of active surveillance programs, including the use of large databases and disparate data sources for rapid signal detection, as well as novel and advanced design and analysis approaches for causal interference from observational data. This book serves as an important reference for pharmacovigilance scientists and pharmacoepidemiologists who are searching for the appropriate study design to answer safety research questions.

Readers will be able to effectively and efficiently design and interpret findings from post-authorization safety studies with the goal of improving the benefit-risk balance of a drug in order to optimize patient safety.

Puntos claves

  • Discusses all types of observational studies in post-marketing drug safety assessment, from spontaneous reporting systems, to pragmatic trials, with examples from real-world settings
  • Presents various types of post-authorization safety studies
  • Offers solutions to the common challenges in the design and conduct of these studies
  • Highlights active surveillance programs, including common data models for rapid signal detection of drug safety issues

De interès para

Pharmaceutical scientists in industry and contract research organizations and specifically, pharmacovigilance scientists, pharmacoepidemiologists, safety surveillance scientists, drug safety physicians and regulatory scientists; regulatory officials and professors and students in these areas and in outcomes research programs

Índice

1. Introduction

2. Risk Management Process

2.1: Risk Assessment

2.2: Risk Minimization

3. Data Sources for PASS

3.1: Health Insurance Administrative Claims

3.2: Electronic Medical Records

3.3: Registries

3.4: Big Data

3.5: Social Media

4. Study Designs for PASS

4.1: Drug Utilization Studies

4.2: Self-Controlled Studies

4.3: Cohort and Nested Case-Control Studies

4.4: Enriched Studies

4.5: Prospective Studies

5. Analytical Approaches for PASS

5.1: Exposure Propensity Scores

5.2: Disease Risk Scores

5.3: Instrumental Variables

5.4: Data Analytic Platforms

5.5: Proactive Safety Surveillance

6. Benefit-Risk Evaluation

6.1: Benefit-Risk Evaluation Frameworks

6.2: Post-Authorization Effectiveness Studies

7. Other PASS

7.1: PASS for Biosimilars and Interchangeable Biologic Products

7.2: PASS for Medical Devices and Combination Products

7.3: PASS for Vaccines

8. EU PAS Register

Detalles del producto

  • Edición: 1
  • Última edición
  • Publicado: 19 de junio de 2018
  • Idioma: Inglés

Sobre los editores

AA

Ayad K. Ali

Dr. Ali is a senior pharmacoepidemiologist at Eli Lilly. He is a Fulbright Scholar and has received many awards from professional and educational organizations, including complimentary memberships, travelships, and research and publication grants. He presented many of his research in pharmacovigilance and drug safety in national and international venues, and published in peer-reviewed journals. Additionally, he received memberships by election to the American College of Epidemiology and Sigma Xi the Scientific Research Society. He is a pharmacist by training and combines extensive experience in pharmacy practice in community, industrial, and academic settings, especially in pharmacoepidemiologic research and pharmacovigilance applications.
Afiliaciones y experiencia
Senior Pharmacoepidemiologist, Global Patient Safety, Eli Lilly and Company, IN, USA

AH

Abraham G. Hartzema

Dr. Hartzema is an eminent scholar and professor at College of Pharmacy, University of Florida, he served as the academic advisor to Dr. Ali and has extensive experience in pharmacoepidemiology and drug risk management. He is the editor of several books in the area of pharmacoepidemiology, and published numerous research and expert opinion articles in peer-reviewed journals. He also served as the lead scientist for the active surveillance sentinel initiative by the Food and Drug Administration. He also appears in several editions of Who’s Who volumes.
Afiliaciones y experiencia
Professor and Eminent Scholar, Department of Pharmaceutical Outcomes and Policy, College of Pharmacy, University of Florida, Gainesville, FL, USA

Ver libro en ScienceDirect

Lee Post-Authorization Safety Studies of Medicinal Products en ScienceDirect